Bavarian Nordic signs EU smallpox and mpox vaccine contract for up to 8 million doses

Core Insights - Bavarian Nordic has secured a new contract with the European Commission, enabling European countries to purchase up to eight million doses of its smallpox and mpox vaccine over the next four years [1] Group 1 - The contract allows for the procurement of vaccines, indicating a significant demand for smallpox and mpox vaccination in Europe [1] - The agreement spans a four-year period, suggesting a long-term commitment to public health initiatives in the region [1] - This development may enhance Bavarian Nordic's market position and revenue potential in the vaccine sector [1]